Dulal S, et al. - In a randomized, phase 2 trial including patients who receive highly emetogenic chemotherapy (HEC), researchers assessed olanzapine (OLN; a higher-cost drug) vs haloperidol (HAL; a lower-cost drug) as a preventive for chemotherapy-induced nausea and vomiting (CINV), focusing on the efficacies and toxicities of these agents. In a random manner, patients were administered either OLN 10 mg orally on days 1 to 4 or HAL 1 mg orally on day 1 and 0.5 mg twice daily on days 2 to 4. On day 1, ondansetron 16 mg and dexamethasone 12 mg were administered intravenously to both groups. They randomly assigned 65 patients, and 64 actually received their allocated treatment (n=32 in each arm). Findings revealed that the efficacy of HAL in the management of CINV was similar to that of OLN, indicating it as the higher-value choice in patients who receive HEC in resource-scarce countries.